Login Register Cart 0
Generic placeholder image

当代阿耳茨海默病研究

Editor-in-Chief

ISSN (Print): 1567-2050
ISSN (Online): 1875-5828

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in English
Review Article

质子泵抑制剂与痴呆症之间的类似 Janus 关联

卷 18, 期 6, 2021

发表于: 29 September, 2021

页: [453 - 469] 页: 17

弟呕挨: 10.2174/1567205018666210929144740

open access plus

摘要

早期的药物流行病学研究表明，质子泵抑制剂 (PPI) 可能会增加阿尔茨海默病 (AD)和非AD相关痴呆症的风险。这些发现得到了临床前研究的支持，特别强调了 PPI 的促淀粉样蛋白和间接抗胆碱能作用。 然而，进一步的大规模药物流行病学研究显示，关于 PPI 与痴呆之间关联的结果不一致。 在药效学上，这些发现可能与 LXR/RXR 介导的淀粉样蛋白清除作用和 PPI 的抗炎作用有关。 影响 PPI 对 AD 影响的其他方面与患者特异性药代动力学和药物基因组学特征有关。 总之，需要个性化（个体化）医学方法来建模和预测 PPI 在未来 AD 和非 AD 相关痴呆症中的潜在有害或有益影响。

关键词: 阿尔茨海默病、痴呆、LXR、药效学、药物流行病学、药物基因组学、药代动力学、PPARγ、质子泵抑制剂、RXR。

Next »
[1]
Savarino E, Marabotto E, Zentilin P, et al. A safety review of proton pump inhibitors to treat acid-related digestive diseases. Expert Opin Drug Saf 2018; 17(8): 785-94.
[http://dx.doi.org/10.1080/14740338.2018.1497155] [PMID: 30035645]
[2]
Shin JM, Sachs G. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep 2008; 10(6): 528-34.
[http://dx.doi.org/10.1007/s11894-008-0098-4] [PMID: 19006606]
[3]
Strand DS, Kim D, Peura DA. 25 Years of proton pump inhibitors: A comprehensive review. Gut Liver 2017; 11(1): 27-37.
[http://dx.doi.org/10.5009/gnl15502] [PMID: 27840364]
[4]
Pinto-Sanchez MI, Yuan Y, Hassan A, Bercik P, Moayyedi P. Proton pump inhibitors for functional dyspepsia. Cochrane Database Syst Rev 2017; 11: CD011194.
[PMID: 29161458]
[5]
Freedberg DE, Kim LS, Yang YX. The risks and benefits of long-term use of proton pump inhibitors: Expert review and best practice advice from the American gastroenterological association. Gastroenterology 2017; 152(4): 706-15.
[http://dx.doi.org/10.1053/j.gastro.2017.01.031] [PMID: 28257716]
[6]
Scarpignato C, Gatta L, Zullo A, Blandizzi C. Group S-A-F, Italian society of pharmacology tIAoHG. . Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression. BMC Med 2016; 14(1): 179.
[http://dx.doi.org/10.1186/s12916-016-0718-z] [PMID: 27825371]
[7]
Goldstein FC, Steenland K, Zhao L, Wharton W, Levey AI, Hajjar I. Proton pump inhibitors and risk of mild cognitive impairment and dementia. J Am Geriatr Soc 2017; 65(9): 1969-74.
[http://dx.doi.org/10.1111/jgs.14956] [PMID: 28590010]
[8]
Juntunen H, Taipale H, Tanskanen A, et al. Long-term use of proton pump inhibitors among community-dwelling persons with and without Alzheimer’s disease. Eur J Clin Pharmacol 2017; 73(9): 1149-58.
[http://dx.doi.org/10.1007/s00228-017-2273-8] [PMID: 28577224]
[9]
WHO. World Health Organization model list of essential medicines: 21st list 2019. World Health Organization 2019. Available from: https://appswhoint/iris/handle/10665/325771
[10]
Shin JM, Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil 2013; 19(1): 25-35.
[http://dx.doi.org/10.5056/jnm.2013.19.1.25] [PMID: 23350044]
[11]
Sachs G, Shin JM, Howden CW. Review article: the clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther 2006; 23(Suppl. 2): 2-8.
[http://dx.doi.org/10.1111/j.1365-2036.2006.02943.x] [PMID: 16700898]
[12]
Helgadottir H, Bjornsson ES. Problems associated with deprescribing of proton pump inhibitors. Int J Mol Sci 2019; 20(21): E5469.
[http://dx.doi.org/10.3390/ijms20215469] [PMID: 31684070]
[13]
Kantor ED, Rehm CD, Haas JS, Chan AT, Giovannucci EL. Trends in prescription drug use among adults in the United States from 1999-2012. JAMA 2015; 314(17): 1818-31.
[http://dx.doi.org/10.1001/jama.2015.13766] [PMID: 26529160]
[14]
Gomm W, von Holt K, Thomé F, et al. Association of proton pump inhibitors with risk of dementia: A pharmacoepidemiological claims data analysis. JAMA Neurol 2016; 73(4): 410-6.
[http://dx.doi.org/10.1001/jamaneurol.2015.4791] [PMID: 26882076]
[15]
Heidelbaugh JJ, Inadomi JM. Magnitude and economic impact of inappropriate use of stress ulcer prophylaxis in non-ICU hospitalized patients. Am J Gastroenterol 2006; 101(10): 2200-5.
[http://dx.doi.org/10.1111/j.1572-0241.2006.00839.x] [PMID: 16952283]
[16]
Eid SM, Boueiz A, Paranji S, Mativo C, Landis R, Abougergi MS. Patterns and predictors of proton pump inhibitor overuse among academic and non-academic hospitalists. Intern Med 2010; 49(23): 2561-8.
[http://dx.doi.org/10.2169/internalmedicine.49.4064] [PMID: 21139293]
[17]
Akter S, Hassan MR, Shahriar M, Akter N, Abbas MG, Bhuiyan MA. Cognitive impact after short-term exposure to different proton pump inhibitors: assessment using CANTAB software. Alzheimers Res Ther 2015; 7: 79.
[http://dx.doi.org/10.1186/s13195-015-0164-8] [PMID: 26714488]
[18]
Mishuk AU, Chen L, Gaillard P, Westrick S, Hansen RA, Qian J. National trends in prescription proton pump inhibitor use and expenditure in the United States in 2002-2017. J Am Pharm Assoc (Wash DC) 2021; 61(1): 7.
[http://dx.doi.org/10.1016/j.japh.2020.09.015]
[19]
Schwabe U, Ludwig W-D. Arzneiverordnungs-Report 2020. Springer 2020.
[http://dx.doi.org/10.1007/978-3-662-62168-4]
[20]
Bublitz M, Poulsen H, Morth JP, Nissen P. In and out of the cation pumps: P-type ATPase structure revisited. Curr Opin Struct Biol 2010; 20(4): 431-9.
[http://dx.doi.org/10.1016/j.sbi.2010.06.007] [PMID: 20634056]
[21]
van Driel IR, Callaghan JM. Proton and potassium transport by H+/K(+)-ATPases. Clin Exp Pharmacol Physiol 1995; 22(12): 952-60.
[http://dx.doi.org/10.1111/j.1440-1681.1995.tb02332.x] [PMID: 8846517]
[22]
Modyanov NN, Petrukhin KE, Sverdlov VE, et al. The family of human Na,K-ATPase genes. ATP1AL1 gene is transcriptionally competent and probably encodes the related ion transport ATPase. FEBS Lett 1991; 278(1): 91-4.
[http://dx.doi.org/10.1016/0014-5793(91)80091-G] [PMID: 1847115]
[23]
Wang D, Hiesinger PR. The vesicular ATPase: a missing link between acidification and exocytosis. J Cell Biol 2013; 203(2): 171-3.
[http://dx.doi.org/10.1083/jcb.201309130] [PMID: 24165933]
[24]
Tabares L, Betz B. Multiple functions of the vesicular proton pump in nerve terminals. Neuron 2010; 68(6): 1020-2.
[http://dx.doi.org/10.1016/j.neuron.2010.12.012] [PMID: 21172605]
[25]
Cheng FC, Ho YF, Hung LC, Chen CF, Tsai TH. Determination and pharmacokinetic profile of omeprazole in rat blood, brain and bile by microdialysis and high-performance liquid chromatography. J Chromatogr A 2002; 949(1-2): 35-42.
[http://dx.doi.org/10.1016/S0021-9673(01)01225-0] [PMID: 11999751]
[26]
Rojo LE, Alzate-Morales J, Saavedra IN, Davies P, Maccioni RB. Selective interaction of lansoprazole and astemizole with tau polymers: potential new clinical use in diagnosis of Alzheimer’s disease. J Alzheimers Dis 2010; 19(2): 573-89.
[http://dx.doi.org/10.3233/JAD-2010-1262] [PMID: 20110603]
[27]
Liang JF, Chen YT, Fuh JL, et al. Proton pump inhibitor-related headaches: a nationwide population-based case-crossover study in Taiwan. Cephalalgia 2015; 35(3): 203-10.
[http://dx.doi.org/10.1177/0333102414535114] [PMID: 24853165]
[28]
Martin RM, Dunn NR, Freemantle S, Shakir S. The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies. Br J Clin Pharmacol 2000; 50(4): 366-72.
[http://dx.doi.org/10.1046/j.1365-2125.2000.00262.x] [PMID: 11012560]
[29]
Chimirri S, Aiello R, Mazzitello C, et al. Vertigo/dizziness as a Drugs’ adverse reaction. J Pharmacol Pharmacother 2013; 4(Suppl. 1): S104-9.
[http://dx.doi.org/10.4103/0976-500X.120969] [PMID: 24347974]
[30]
Hanneken AM, Babai N, Thoreson WB. Oral proton pump inhibitors disrupt horizontal cell-cone feedback and enhance visual hallucinations in macular degeneration patients. Invest Ophthalmol Vis Sci 2013; 54(2): 1485-9.
[http://dx.doi.org/10.1167/iovs.12-11091] [PMID: 23341015]
[31]
Heckmann JG, Birklein F, Neundörfer B. Omeprazole-induced delirium. J Neurol 2000; 247(1): 56-7.
[http://dx.doi.org/10.1007/s004150050011] [PMID: 10701899]
[32]
Yibirin M, De Oliveira D, Valera R, Plitt AE, Lutgen S. Adverse effects associated with proton pump inhibitor use. Cureus 2021; 13(1): e12759.
[PMID: 33614352]
[33]
Cundy T, Dissanayake A. Severe hypomagnesaemia in long-term users of proton-pump inhibitors. Clin Endocrinol (Oxf) 2008; 69(2): 338-41.
[http://dx.doi.org/10.1111/j.1365-2265.2008.03194.x] [PMID: 18221401]
[34]
Gulmez SE, Holm A, Frederiksen H, Jensen TG, Pedersen C, Hallas J. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med 2007; 167(9): 950-5.
[http://dx.doi.org/10.1001/archinte.167.9.950] [PMID: 17502537]
[35]
Howell MD, Novack V, Grgurich P, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med 2010; 170(9): 784-90.
[http://dx.doi.org/10.1001/archinternmed.2010.89] [PMID: 20458086]
[36]
Khalili H, Huang ES, Jacobson BC, Camargo CA Jr, Feskanich D, Chan AT. Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study. BMJ 2012; 344: e372.
[http://dx.doi.org/10.1136/bmj.e372] [PMID: 22294756]
[37]
Perry IE, Sonu I, Scarpignato C, Akiyama J, Hongo M, Vega KJ. Potential proton pump inhibitor-related adverse effects. Ann N Y Acad Sci 2020; 1481(1): 43-58.
[http://dx.doi.org/10.1111/nyas.14428] [PMID: 32761834]
[38]
Yu LY, Sun LN, Zhang XH, et al. A review of the novel application and potential adverse effects of proton pump inhibitors. Adv Ther 2017; 34(5): 1070-86.
[http://dx.doi.org/10.1007/s12325-017-0532-9] [PMID: 28429247]
[39]
Almario CV, Chey WD, Spiegel BMR. Increased risk of COVID-19 among users of proton pump inhibitors. Am J Gastroenterol 2020; 115(10): 1707-15.
[http://dx.doi.org/10.14309/ajg.0000000000000798] [PMID: 32852340]
[40]
Lee SW, Ha EK, Yeniova AO, et al. Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching. Gut 2021; 70(1): 76-84.
[http://dx.doi.org/10.1136/gutjnl-2020-322248] [PMID: 32732368]
[41]
Price E, Treacher DF. Reduced gastric acidity, proton pump inhibitors and increased severity of COVID-19 infections. Crit Care 2021; 25(1): 73.
[http://dx.doi.org/10.1186/s13054-021-03497-6] [PMID: 33602257]
[42]
Prince MWA, Guerchet M, Claire Ali G, Wu Y-T, Prina M. Alzheimer report 2015: the global impact of dementia: An analysis of prevalence, incidence, cost and trends, Alzheimer’s disease international. ADI 2015. Available from: https://www.alzint.org/resource/world-alzheimer-report-2015/
[43]
WHOWorld Health Organization, Dementia: a Public Health Priority. Geneva: World Health Organization 2012. Available from: https://apps.who.int/iris/handle/10665/75263
[44]
Querfurth HW, LaFerla FM. Alzheimer’s disease. N Engl J Med 2010; 362(4): 329-44.
[http://dx.doi.org/10.1056/NEJMra0909142] [PMID: 20107219]
[45]
Matyas N, Auer S, Gisinger C, et al. Continuing education for the prevention of mild cognitive impairment and Alzheimer’s-type dementia: a systematic review protocol. Syst Rev 2017; 6(1): 157.
[http://dx.doi.org/10.1186/s13643-017-0553-0] [PMID: 28789697]
[46]
Rajan KB, Weuve J, Barnes LL, McAninch EA, Wilson RS, Evans DA. Population estimate of people with clinical AD and mild cognitive impairment in the United States (2020-2060). Alzheimers Dement. 2021 May 27. (Online ahead of print).
[http://dx.doi.org/10.1002/alz.12362]
[47]
Report As A. 2021 Alzheimer’s disease facts and figures. Alzheimers Dement 2021; 17(3): 327-406.
[http://dx.doi.org/10.1002/alz.12328] [PMID: 33756057]
[48]
Rajan KB, Weuve J, Barnes LL, Wilson RS, Evans DA. Prevalence and incidence of clinically diagnosed Alzheimer’s disease dementia from 1994 to 2012 in a population study. Alzheimers Dement 2019; 15(1): 1-7.
[http://dx.doi.org/10.1016/j.jalz.2018.07.216] [PMID: 30195482]
[49]
Tom SE, Hubbard RA, Crane PK, et al. Characterization of dementia and Alzheimer’s disease in an older population: updated incidence and life expectancy with and without dementia. Am J Public Health 2015; 105(2): 408-13.
[http://dx.doi.org/10.2105/AJPH.2014.301935] [PMID: 25033130]
[50]
Hebert LE, Beckett LA, Scherr PA, Evans DA. Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050. Alzheimer Dis Assoc Disord 2001; 15(4): 169-73.
[http://dx.doi.org/10.1097/00002093-200110000-00002] [PMID: 11723367]
[51]
Hebert LE, Bienias JL, Aggarwal NT, et al. Change in risk of Alzheimer disease over time. Neurology 2010; 75(9): 786-91.
[http://dx.doi.org/10.1212/WNL.0b013e3181f0754f] [PMID: 20805524]
[52]
Nelson PT, Head E, Schmitt FA, et al. Alzheimer’s disease is not “brain aging”: neuropathological, genetic, and epidemiological human studies. Acta Neuropathol 2011; 121(5): 571-87.
[http://dx.doi.org/10.1007/s00401-011-0826-y] [PMID: 21516511]
[53]
Chêne G, Beiser A, Au R, et al. Gender and incidence of dementia in the Framingham Heart Study from mid-adult life. Alzheimers Dement 2015; 11(3): 310-20.
[http://dx.doi.org/10.1016/j.jalz.2013.10.005] [PMID: 24418058]
[54]
Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer’s disease. Neurology 1993; 43(8): 1467-72.
[http://dx.doi.org/10.1212/WNL.43.8.1467] [PMID: 8350998]
[55]
Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. JAMA 1997; 278(16): 1349-56.
[http://dx.doi.org/10.1001/jama.1997.03550160069041] [PMID: 9343467]
[56]
Rajan KB, Barnes LL, Wilson RS, et al. Racial differences in the association between apolipoprotein E risk alleles and overall and total cardiovascular mortality over 18 years. J Am Geriatr Soc 2017; 65(11): 2425-30.
[http://dx.doi.org/10.1111/jgs.15059] [PMID: 28898389]
[57]
Evans DA, Bennett DA, Wilson RS, et al. Incidence of Alzheimer disease in a biracial urban community: relation to apolipoprotein E allele status. Arch Neurol 2003; 60(2): 185-9.
[http://dx.doi.org/10.1001/archneur.60.2.185] [PMID: 12580702]
[58]
Tang MX, Stern Y, Marder K, et al. The APOE-epsilon4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. JAMA 1998; 279(10): 751-5.
[http://dx.doi.org/10.1001/jama.279.10.751] [PMID: 9508150]
[59]
Loy CT, Schofield PR, Turner AM, Kwok JB. Genetics of dementia. Lancet 2014; 383(9919): 828-40.
[http://dx.doi.org/10.1016/S0140-6736(13)60630-3] [PMID: 23927914]
[60]
Holtzman DM, Herz J, Bu G. Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb Perspect Med 2012; 2(3): a006312.
[http://dx.doi.org/10.1101/cshperspect.a006312] [PMID: 22393530]
[61]
Michaelson DM. APOE ε4: the most prevalent yet understudied risk factor for Alzheimer’s disease. Alzheimers Dement 2014; 10(6): 861-8.
[http://dx.doi.org/10.1016/j.jalz.2014.06.015] [PMID: 25217293]
[62]
Jansen WJ, Ossenkoppele R, Knol DL, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA 2015; 313(19): 1924-38.
[http://dx.doi.org/10.1001/jama.2015.4668] [PMID: 25988462]
[63]
Spinney L. Alzheimer’s disease: The forgetting gene. Nature 2014; 510(7503): 26-8.
[http://dx.doi.org/10.1038/510026a] [PMID: 24899289]
[64]
Mayeux R, Saunders AM, Shea S, et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer’s disease. N Engl J Med 1998; 338(8): 506-11.
[http://dx.doi.org/10.1056/NEJM199802193380804] [PMID: 9468467]
[65]
Ward A, Crean S, Mercaldi CJ, et al. Prevalence of apolipoprotein E4 genotype and homozygotes (APOE e4/4) among patients diagnosed with Alzheimer’s disease: a systematic review and meta-analysis. Neuroepidemiology 2012; 38(1): 1-17.
[http://dx.doi.org/10.1159/000334607] [PMID: 22179327]
[66]
Dekhtyar S, Marseglia A, Xu W, Darin-Mattsson A, Wang HX, Fratiglioni L. Genetic risk of dementia mitigated by cognitive reserve: A cohort study. Ann Neurol 2019; 86(1): 68-78.
[http://dx.doi.org/10.1002/ana.25501] [PMID: 31066941]
[67]
Bekris LM, Yu CE, Bird TD, Tsuang DW. Genetics of Alzheimer disease. J Geriatr Psychiatry Neurol 2010; 23(4): 213-27.
[http://dx.doi.org/10.1177/0891988710383571] [PMID: 21045163]
[68]
Goldman JS, Hahn SE, Catania JW, et al. Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. Genet Med 2011; 13(6): 597-605.
[http://dx.doi.org/10.1097/GIM.0b013e31821d69b8] [PMID: 21577118]
[69]
Snyder HM, Bain LJ, Brickman AM, et al. Further understanding the connection between Alzheimer’s disease and Down syndrome. Alzheimers Dement 2020; 16(7): 1065-77.
[http://dx.doi.org/10.1002/alz.12112] [PMID: 32544310]
[70]
Green RC, Cupples LA, Go R, et al. Risk of dementia among white and African American relatives of patients with Alzheimer disease. JAMA 2002; 287(3): 329-36.
[http://dx.doi.org/10.1001/jama.287.3.329] [PMID: 11790212]
[71]
Lautenschlager NT, Cupples LA, Rao VS, et al. Risk of dementia among relatives of Alzheimer’s disease patients in the MIRAGE study: What is in store for the oldest old? Neurology 1996; 46(3): 641-50.
[http://dx.doi.org/10.1212/WNL.46.3.641] [PMID: 8618660]
[72]
Vermunt L, Sikkes SAM, van den Hout A, et al. Duration of preclinical, prodromal, and dementia stages of Alzheimer’s disease in relation to age, sex, and APOE genotype. Alzheimers Dement 2019; 15(7): 888-98.
[http://dx.doi.org/10.1016/j.jalz.2019.04.001] [PMID: 31164314]
[73]
Samieri C, Perier MC, Gaye B, et al. Association of cardiovascular health level in older age with cognitive decline and incident dementia. JAMA 2018; 320(7): 657-64.
[http://dx.doi.org/10.1001/jama.2018.11499] [PMID: 30140876]
[74]
Anstey KJ, von Sanden C, Salim A, O’Kearney R. Smoking as a risk factor for dementia and cognitive decline: a meta-analysis of prospective studies. Am J Epidemiol 2007; 166(4): 367-78.
[http://dx.doi.org/10.1093/aje/kwm116] [PMID: 17573335]
[75]
Rusanen M, Kivipelto M, Quesenberry CP Jr, Zhou J, Whitmer RA. Heavy smoking in midlife and long-term risk of Alzheimer disease and vascular dementia. Arch Intern Med 2011; 171(4): 333-9.
[http://dx.doi.org/10.1001/archinternmed.2010.393] [PMID: 20975015]
[76]
Beydoun MA, Beydoun HA, Gamaldo AA, Teel A, Zonderman AB, Wang Y. Epidemiologic studies of modifiable factors associated with cognition and dementia: systematic review and meta-analysis. BMC Public Health 2014; 14: 643.
[http://dx.doi.org/10.1186/1471-2458-14-643] [PMID: 24962204]
[77]
Ohara T, Ninomiya T, Hata J, et al. Midlife and late-life smoking and risk of dementia in the community: The hisayama study. J Am Geriatr Soc 2015; 63(11): 2332-9.
[http://dx.doi.org/10.1111/jgs.13794] [PMID: 26503243]
[78]
Choi D, Choi S, Park SM. Effect of smoking cessation on the risk of dementia: A longitudinal study. Ann Clin Transl Neurol 2018; 5(10): 1192-9.
[http://dx.doi.org/10.1002/acn3.633] [PMID: 30349854]
[79]
Wu W, Brickman AM, Luchsinger J, et al. The brain in the age of old: the hippocampal formation is targeted differentially by diseases of late life. Ann Neurol 2008; 64(6): 698-706.
[http://dx.doi.org/10.1002/ana.21557] [PMID: 19107993]
[80]
Gudala K, Bansal D, Schifano F, Bhansali A. Diabetes mellitus and risk of dementia: A meta-analysis of prospective observational studies. J Diabetes Investig 2013; 4(6): 640-50.
[http://dx.doi.org/10.1111/jdi.12087] [PMID: 24843720]
[81]
Vagelatos NT, Eslick GD. Type 2 diabetes as a risk factor for Alzheimer’s disease: the confounders, interactions, and neuropathology associated with this relationship. Epidemiol Rev 2013; 35: 152-60.
[http://dx.doi.org/10.1093/epirev/mxs012] [PMID: 23314404]
[82]
Reitz C, Brayne C, Mayeux R. Epidemiology of Alzheimer disease. Nat Rev Neurol 2011; 7(3): 137-52.
[http://dx.doi.org/10.1038/nrneurol.2011.2] [PMID: 21304480]
[83]
Rönnemaa E, Zethelius B, Lannfelt L, Kilander L. Vascular risk factors and dementia: 40-year follow-up of a population-based cohort. Dement Geriatr Cogn Disord 2011; 31(6): 460-6.
[http://dx.doi.org/10.1159/000330020] [PMID: 21791923]
[84]
Kivimäki M, Luukkonen R, Batty GD, et al. Body mass index and risk of dementia: Analysis of individual-level data from 1.3 million individuals. Alzheimers Dement 2018; 14(5): 601-9.
[http://dx.doi.org/10.1016/j.jalz.2017.09.016] [PMID: 29169013]
[85]
Loef M, Walach H. Midlife obesity and dementia: meta-analysis and adjusted forecast of dementia prevalence in the United States and China. Obesity (Silver Spring) 2013; 21(1): E51-5.
[http://dx.doi.org/10.1002/oby.20037] [PMID: 23401370]
[86]
Anstey KJ, Cherbuin N, Budge M, Young J. Body mass index in midlife and late-life as a risk factor for dementia: a meta-analysis of prospective studies. Obes Rev 2011; 12(5): e426-37.
[http://dx.doi.org/10.1111/j.1467-789X.2010.00825.x] [PMID: 21348917]
[87]
Gottesman RF, Albert MS, Alonso A, et al. Associations between midlife vascular risk factors and 25-year incident dementia in the atherosclerosis risk in communities (ARIC) cohort. JAMA Neurol 2017; 74(10): 1246-54.
[http://dx.doi.org/10.1001/jamaneurol.2017.1658] [PMID: 28783817]
[88]
Abell JG, Kivimäki M, Dugravot A, et al. Association between systolic blood pressure and dementia in the Whitehall II cohort study: role of age, duration, and threshold used to define hypertension. Eur Heart J 2018; 39(33): 3119-25.
[http://dx.doi.org/10.1093/eurheartj/ehy288] [PMID: 29901708]
[89]
Ninomiya T, Ohara T, Hirakawa Y, et al. Midlife and late-life blood pressure and dementia in Japanese elderly: the Hisayama study. Hypertension 2011; 58(1): 22-8.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.110.163055] [PMID: 21555680]
[90]
Debette S, Seshadri S, Beiser A, et al. Midlife vascular risk factor exposure accelerates structural brain aging and cognitive decline. Neurology 2011; 77(5): 461-8.
[http://dx.doi.org/10.1212/WNL.0b013e318227b227] [PMID: 21810696]
[91]
Livingston G, Sommerlad A, Orgeta V, et al. Dementia prevention, intervention, and care. Lancet 2017; 390(10113): 2673-734.
[http://dx.doi.org/10.1016/S0140-6736(17)31363-6] [PMID: 28735855]
[92]
Solomon A, Kivipelto M, Wolozin B, Zhou J, Whitmer RA. Midlife serum cholesterol and increased risk of Alzheimer’s and vascular dementia three decades later. Dement Geriatr Cogn Disord 2009; 28(1): 75-80.
[http://dx.doi.org/10.1159/000231980] [PMID: 19648749]
[93]
Meng XF, Yu JT, Wang HF, et al. Midlife vascular risk factors and the risk of Alzheimer’s disease: a systematic review and meta-analysis. J Alzheimers Dis 2014; 42(4): 1295-310.
[http://dx.doi.org/10.3233/JAD-140954] [PMID: 25024338]
[94]
Aisen PS, Cummings J, Jack CR Jr, et al. On the path to 2025: understanding the Alzheimer’s disease continuum. Alzheimers Res Ther 2017; 9(1): 60.
[http://dx.doi.org/10.1186/s13195-017-0283-5] [PMID: 28793924]
[95]
Rehm J, Hasan OSM, Black SE, Shield KD, Schwarzinger M. Alcohol use and dementia: a systematic scoping review. Alzheimers Res Ther 2019; 11(1): 1.
[http://dx.doi.org/10.1186/s13195-018-0453-0] [PMID: 30611304]
[96]
Cherbuin N, Kim S, Anstey KJ. Dementia risk estimates associated with measures of depression: a systematic review and meta-analysis. BMJ Open 2015; 5(12): e008853.
[http://dx.doi.org/10.1136/bmjopen-2015-008853] [PMID: 26692556]
[97]
Thomson RS, Auduong P, Miller AT, Gurgel RK. Hearing loss as a risk factor for dementia: a systematic review. Laryngoscope Investig Otolaryngol 2017; 2(2): 69-79.
[http://dx.doi.org/10.1002/lio2.65] [PMID: 28894825]
[98]
Fitzpatrick AL, Kuller LH, Lopez OL, et al. Midlife and late-life obesity and the risk of dementia: cardiovascular health study. Arch Neurol 2009; 66(3): 336-42.
[http://dx.doi.org/10.1001/archneurol.2008.582] [PMID: 19273752]
[99]
Corrada MM, Hayden KM, Paganini-Hill A, et al. Age of onset of hypertension and risk of dementia in the oldest-old: The 90+ Study. Alzheimers Dement 2017; 13(2): 103-10.
[http://dx.doi.org/10.1016/j.jalz.2016.09.007] [PMID: 28108119]
[100]
Barnes DE, Byers AL, Gardner RC, Seal KH, Boscardin WJ, Yaffe K. Association of mild traumatic brain injury with and without loss of consciousness with dementia in US military veterans. JAMA Neurol 2018; 75(9): 1055-61.
[http://dx.doi.org/10.1001/jamaneurol.2018.0815] [PMID: 29801145]
[101]
Asken BM, Sullan MJ, DeKosky ST, Jaffee MS, Bauer RM. Research gaps and controversies in chronic traumatic encephalopathy: A review. JAMA Neurol 2017; 74(10): 1255-62.
[http://dx.doi.org/10.1001/jamaneurol.2017.2396] [PMID: 28975240]
[102]
Bernard SM, McGeehin MA. Prevalence of blood lead levels >or= 5 micro g/dL among US children 1 to 5 years of age and socioeconomic and demographic factors associated with blood of lead levels 5 to 10 micro g/dL, Third National Health and Nutrition Examination Survey, 1988-1994. Pediatrics 2003; 112(6 Pt 1): 1308-13.
[http://dx.doi.org/10.1542/peds.112.6.1308] [PMID: 14654602]
[103]
Griffith M, Tajik M, Wing S. Patterns of agricultural pesticide use in relation to socioeconomic characteristics of the population in the rural U.S. South. Int J Health Serv 2007; 37(2): 259-77.
[http://dx.doi.org/10.2190/R410-7263-4811-4415] [PMID: 17665723]
[104]
Lin FC, Chen CY, Lin CW, Wu MT, Chen HY, Huang P. Air pollution is associated with cognitive deterioration of Alzheimer’s disease. Gerontology 2021; 1-9.
[http://dx.doi.org/10.1159/000515162] [PMID: 33882496]
[105]
Younan D, Petkus AJ, Widaman KF, et al. Particulate matter and episodic memory decline mediated by early neuroanatomic biomarkers of Alzheimer’s disease. Brain 2020; 143(1): 289-302.
[http://dx.doi.org/10.1093/brain/awz348] [PMID: 31746986]
[106]
Peters R, Ee N, Peters J, Booth A, Mudway I, Anstey KJ. Air pollution and dementia: A systematic review. J Alzheimers Dis 2019; 70(s1): S145-63.
[http://dx.doi.org/10.3233/JAD-180631] [PMID: 30775976]
[107]
Kulick ER, Wellenius GA, Boehme AK, et al. Long-term exposure to air pollution and trajectories of cognitive decline among older adults. Neurology 2020; 94(17): e1782-92.
[http://dx.doi.org/10.1212/WNL.0000000000009314] [PMID: 32269113]
[108]
Fitzpatrick AL, Kuller LH, Ives DG, et al. Incidence and prevalence of dementia in the cardiovascular health study. J Am Geriatr Soc 2004; 52(2): 195-204.
[http://dx.doi.org/10.1111/j.1532-5415.2004.52058.x] [PMID: 14728627]
[109]
Kukull WA, Higdon R, Bowen JD, et al. Dementia and Alzheimer disease incidence: a prospective cohort study. Arch Neurol 2002; 59(11): 1737-46.
[http://dx.doi.org/10.1001/archneur.59.11.1737] [PMID: 12433261]
[110]
Sando SB, Melquist S, Cannon A, et al. Risk-reducing effect of education in Alzheimer’s disease. Int J Geriatr Psychiatry 2008; 23(11): 1156-62.
[http://dx.doi.org/10.1002/gps.2043] [PMID: 18484674]
[111]
Stern Y. Cognitive reserve in ageing and Alzheimer’s disease. Lancet Neurol 2012; 11(11): 1006-12.
[http://dx.doi.org/10.1016/S1474-4422(12)70191-6] [PMID: 23079557]
[112]
Hendrie HC, Smith-Gamble V, Lane KA, Purnell C, Clark DO, Gao S. The association of early life factors and declining incidence rates of dementia in an elderly population of African Americans. J Gerontol B Psychol Sci Soc Sci 2018; 73(Suppl. 1): S82-9.
[http://dx.doi.org/10.1093/geronb/gbx143] [PMID: 29669098]
[113]
Stern Y, Arenaza-Urquijo EM, Bartrés-Faz D, et al. Whitepaper: Defining and investigating cognitive reserve, brain reserve, and brain maintenance. Alzheimers Dement 2020; 16(9): 1305-11.
[http://dx.doi.org/10.1016/j.jalz.2018.07.219] [PMID: 30222945]
[114]
Menke A, Casagrande S, Geiss L, Cowie CC. Prevalence of and trends in diabetes among adults in the United States, 1988-2012. JAMA 2015; 314(10): 1021-9.
[http://dx.doi.org/10.1001/jama.2015.10029] [PMID: 26348752]
[115]
Sims M, Diez Roux AV, Boykin S, et al. The socioeconomic gradient of diabetes prevalence, awareness, treatment, and control among African Americans in the jackson heart study. Ann Epidemiol 2011; 21(12): 892-8.
[http://dx.doi.org/10.1016/j.annepidem.2011.05.006] [PMID: 21737303]
[116]
Lee TC, Glynn RJ, Peña JM, et al. Socioeconomic status and incident type 2 diabetes mellitus: data from the Women’s Health Study. PLoS One 2011; 6(12): e27670.
[http://dx.doi.org/10.1371/journal.pone.0027670] [PMID: 22194788]
[117]
Gillespie CD, Hurvitz KA. Centers for Disease Control and Prevention (CDC). Prevalence of hypertension and controlled hypertension - United States, 2007-2010. MMWR Suppl 2013; 62(3): 144-8.
[PMID: 24264505]
[118]
Durazzo TC, Mattsson N, Weiner MW. Alzheimer’s disease neuroimaging initiative. Smoking and increased Alzheimer’s disease risk: A review of potential mechanisms. Alzheimers Dement 2014; 10(3): S122-45.
[http://dx.doi.org/10.1016/j.jalz.2014.04.009] [PMID: 24924665]
[119]
Haenisch B, von Holt K, Wiese B, et al. Risk of dementia in elderly patients with the use of proton pump inhibitors. Eur Arch Psychiatry Clin Neurosci 2015; 265(5): 419-28.
[http://dx.doi.org/10.1007/s00406-014-0554-0] [PMID: 25341874]
[120]
Kuller LH. Do proton pump inhibitors increase the risk of dementia? JAMA Neurol 2016; 73(4): 379-81.
[http://dx.doi.org/10.1001/jamaneurol.2015.4931] [PMID: 26882528]
[121]
Wise J. Proton pump inhibitors may be linked to dementia risk. BMJ 2016; 352: i972.
[http://dx.doi.org/10.1136/bmj.i972] [PMID: 26888541]
[122]
Zuercher S. Développement des démences: les inhibiteurs de la pompe à protons impliqués? Rev Med Suisse 2016; 12(513): 716.
[PMID: 27197331]
[123]
Waldum HL. Proton pump inhibitors and gastric cancer. Tidsskr Nor Laegeforen 2016; 136(1): 13-4.
[http://dx.doi.org/10.4045/tidsskr.15.1032] [PMID: 26757651]
[124]
Venci JV, Eisenberg KW. Proton pump inhibitors and dementia incidence. JAMA Neurol 2016; 73(8): 1026.
[http://dx.doi.org/10.1001/jamaneurol.2016.1500] [PMID: 27322351]
[125]
Freeman WD. Proton pump inhibitors and dementia incidence. JAMA Neurol 2016; 73(8): 1026-7.
[http://dx.doi.org/10.1001/jamaneurol.2016.1503] [PMID: 27322437]
[126]
Sharma K, Minagar A, Sun H. Proton pump inhibitors and dementia incidence. JAMA Neurol 2016; 73(8): 1027.
[http://dx.doi.org/10.1001/jamaneurol.2016.1959] [PMID: 27322567]
[127]
Nguyen L, Hur C. Proton pump inhibitors and dementia incidence. JAMA Neurol 2016; 73(8): 1027-8.
[http://dx.doi.org/10.1001/jamaneurol.2016.1962] [PMID: 27322752]
[128]
Keller DL. Proton pump inhibitors and dementia incidence. JAMA Neurol 2016; 73(8): 1025.
[http://dx.doi.org/10.1001/jamaneurol.2016.1488] [PMID: 27323287]
[129]
Kawada T. Proton pump inhibitors and dementia incidence. JAMA Neurol 2016; 73(8): 1025-6.
[http://dx.doi.org/10.1001/jamaneurol.2016.1491] [PMID: 27323321]
[130]
Huat TJ, Camats-Perna J, Newcombe EA, Valmas N, Kitazawa M, Medeiros R. Metal toxicity links to Alzheimer’s disease and neuroinflammation. J Mol Biol 2019; 431(9): 1843-68.
[http://dx.doi.org/10.1016/j.jmb.2019.01.018] [PMID: 30664867]
[131]
Wang Z, Wei X, Yang J, et al. Chronic exposure to aluminum and risk of Alzheimer’s disease: A meta-analysis. Neurosci Lett 2016; 610: 200-6.
[http://dx.doi.org/10.1016/j.neulet.2015.11.014] [PMID: 26592479]
[132]
Wijarnpreecha K, Thongprayoon C, Panjawatanan P, Ungprasert P. Proton pump inhibitors and risk of dementia. Ann Transl Med 2016; 4(12): 240.
[http://dx.doi.org/10.21037/atm.2016.06.14] [PMID: 27429966]
[133]
Badiola N, Alcalde V, Pujol A, et al. The proton-pump inhibitor lansoprazole enhances amyloid beta production. PLoS One 2013; 8(3): e58837.
[http://dx.doi.org/10.1371/journal.pone.0058837] [PMID: 23520537]
[134]
Kumar R, Kumar A, Nordberg A, Långström B, Darreh-Shori T. Proton pump inhibitors act with unprecedented potencies as inhibitors of the acetylcholine biosynthesizing enzyme-A plausible missing link for their association with incidence of dementia. Alzheimers Dement 2020; 16(7): 1031-42.
[http://dx.doi.org/10.1002/alz.12113] [PMID: 32383816]
[135]
Ortiz-Guerrero G, Amador-Muñoz D, Calderón-Ospina CA, López-Fuentes D, Nava Mesa MO. Proton pump inhibitors and dementia: physiopathological mechanisms and clinical consequences. Neural Plast 2018; 2018: 5257285.
[http://dx.doi.org/10.1155/2018/5257285] [PMID: 29755512]
[136]
Booker A, Jacob LE, Rapp M, Bohlken J, Kostev K. Risk factors for dementia diagnosis in German primary care practices. Int Psychogeriatr 2016; 28(7): 1059-65.
[http://dx.doi.org/10.1017/S1041610215002082] [PMID: 26744954]
[137]
Taipale H, Tolppanen AM, Tiihonen M, Tanskanen A, Tiihonen J, Hartikainen S. No association between proton pump inhibitor use and risk of Alzheimer’s disease. Am J Gastroenterol 2017; 112(12): 1802-8.
[http://dx.doi.org/10.1038/ajg.2017.196] [PMID: 28695906]
[138]
Lochhead P, Hagan K, Joshi AD, et al. Association between proton pump inhibitor use and cognitive function in women. Gastroenterology 2017; 153(4): 971-979.e4.
[http://dx.doi.org/10.1053/j.gastro.2017.06.061] [PMID: 28728964]
[139]
Gray SL, Walker RL, Dublin S, et al. Proton pump inhibitor use and dementia risk: Prospective population-based study. J Am Geriatr Soc 2018; 66(2): 247-53.
[http://dx.doi.org/10.1111/jgs.15073] [PMID: 29134629]
[140]
Moayyedi P, Lewis MA. Proton pump inhibitors and dementia: Deciphering the data. Am J Gastroenterol 2017; 112(12): 1809-11.
[http://dx.doi.org/10.1038/ajg.2017.415] [PMID: 29215629]
[141]
Batchelor R, Gilmartin JF, Kemp W, Hopper I, Liew D. Dementia, cognitive impairment and proton pump inhibitor therapy: A systematic review. J Gastroenterol Hepatol 2017; 32(8): 1426-35.
[http://dx.doi.org/10.1111/jgh.13750] [PMID: 28128476]
[142]
Imfeld P, Bodmer M, Jick SS, Meier CR. Proton pump inhibitor use and risk of developing Alzheimer’s disease or vascular dementia: A case-control analysis. Drug Saf 2018; 41(12): 1387-96.
[http://dx.doi.org/10.1007/s40264-018-0704-9] [PMID: 30146658]
[143]
Hwang IC, Chang J, Park SM. A nationwide population-based cohort study of dementia risk among acid suppressant users. Am J Geriatr Psychiatry 2018; 26(11): 1175-83.
[http://dx.doi.org/10.1016/j.jagp.2018.06.002] [PMID: 30072307]
[144]
Cooksey R, Kennedy J, Dennis MS, et al. Proton pump inhibitors and dementia risk: Evidence from a cohort study using linked routinely collected national health data in Wales, UK. PLoS One 2020; 15(9): e0237676.
[http://dx.doi.org/10.1371/journal.pone.0237676] [PMID: 32946449]
[145]
Torres-Bondia F, Dakterzada F, Galván L, et al. Proton pump inhibitors and the risk of Alzheimer’s disease and non-Alzheimer’s dementias. Sci Rep 2020; 10(1): 21046.
[http://dx.doi.org/10.1038/s41598-020-78199-0] [PMID: 33273636]
[146]
Collin BG, Raju D, Altman J, Katsikas S. The effects of proton pump inhibitors on neuropsychological functioning. Appl Neuropsychol Adult 2021; 1-10. (Online ahead of print).
[http://dx.doi.org/10.1080/23279095.2021.1883019] [PMID: 33651951]
[147]
Ahn N, Frenzel S, Wittfeld K, et al. Lack of association between proton pump inhibitor use and brain aging: a cross-sectional study. Eur J Clin Pharmacol 2021; 77(7): 1039-48.
[http://dx.doi.org/10.1007/s00228-020-03068-8] [PMID: 33442768]
[148]
Li M, Luo Z, Yu S, Tang Z. Proton pump inhibitor use and risk of dementia: Systematic review and meta-analysis. Medicine (Baltimore) 2019; 98(7): e14422.
[http://dx.doi.org/10.1097/MD.0000000000014422] [PMID: 30762748]
[149]
Desai M, Nutalapati V, Srinivasan S, et al. Proton pump inhibitors do not increase the risk of dementia: a systematic review and meta-analysis of prospective studies. Dis Esophagus 2020; 33(10): doaa041.
[http://dx.doi.org/10.1093/dote/doaa041] [PMID: 32476013]
[150]
Khan MA, Yuan Y, Iqbal U, et al. No association linking short-term proton pump inhibitor use to dementia: Systematic review and meta-analysis of observational studies. Am J Gastroenterol 2020; 115(5): 671-8.
[http://dx.doi.org/10.14309/ajg.0000000000000500] [PMID: 31895707]
[151]
Song YQ, Li Y, Zhang SL, Gao J, Feng SY. Proton pump inhibitor use does not increase dementia and Alzheimer’s disease risk: An updated meta-analysis of published studies involving 642305 patients. PLoS One 2019; 14(7): e0219213.
[http://dx.doi.org/10.1371/journal.pone.0219213] [PMID: 31265473]
[152]
Zhang Y, Liang M, Sun C, et al. Proton pump inhibitors use and dementia risk: a meta-analysis of cohort studies. Eur J Clin Pharmacol 2020; 76(2): 139-47.
[http://dx.doi.org/10.1007/s00228-019-02753-7] [PMID: 31748819]
[153]
Zhang Y, Zhan J, Bao Q, Lu J, Tan L. Possible dementia risk of proton pump inhibitors and H2 receptor blockers use in the treatment of Helicobacter pylori: A meta-analysis study. Med Hypotheses 2020; 144: 109989.
[http://dx.doi.org/10.1016/j.mehy.2020.109989] [PMID: 32563971]
[154]
Thunell J, Chen Y, Joyce G, et al. Drug therapies for chronic conditions and risk of Alzheimer’s disease and related dementias: A scoping review. Alzheimers Dement 2021; 17(1): 41-8.
[http://dx.doi.org/10.1002/alz.12175] [PMID: 33090701]
[155]
Chen LY, Lin HJ, Wu WT, et al. Clinical use of acid suppressants and risk of dementia in the elderly: A pharmaco-epidemiological cohort study. Int J Environ Res Public Health 2020; 17(21): E8271.
[http://dx.doi.org/10.3390/ijerph17218271] [PMID: 33182362]
[156]
Wu CL, Lei WY, Wang JS, Lin CE, Chen CL, Wen SH. Acid suppressants use and the risk of dementia: A population-based propensity score-matched cohort study. PLoS One 2020; 15(11): e0242975.
[http://dx.doi.org/10.1371/journal.pone.0242975] [PMID: 33253311]
[157]
Tai SY, Chien CY, Wu DC, et al. Risk of dementia from proton pump inhibitor use in Asian population: A nationwide cohort study in Taiwan. PLoS One 2017; 12(2): e0171006.
[http://dx.doi.org/10.1371/journal.pone.0171006] [PMID: 28199356]
[158]
Herghelegui AM, Prada GI, Nacu R. Prolonged use of proton pump inhibitors and cognitive function in older adults. Farmacia 2016; (64): 262-7.
[159]
Bebarta VS, King JA, McDonough M. Proton pump inhibitor-induced rhabdomyolysis and hyponatremic delirium. Am J Emerg Med 2008; 26(4): 519 e1-2.
[http://dx.doi.org/10.1016/j.ajem.2007.08.026]
[160]
Delgado MG, Calleja S, Suarez L, Pascual J. Recurrent confusional episodes associated with hypomagnesaemia due to esomeprazol. BMJ Case Rep 2013; 2013: bcr2013200501.
[http://dx.doi.org/10.1136/bcr-2013-200501]
[161]
Pasina L, Zanotta D, Puricelli S, Bonoldi G. Acute neurological symptoms secondary to hypomagnesemia induced by proton pump inhibitors: a case series. Eur J Clin Pharmacol 2016; 72(5): 641-3.
[http://dx.doi.org/10.1007/s00228-016-2024-2] [PMID: 26874835]
[162]
Fujii S, Tanimukai H, Kashiwagi Y. Comparison and analysis of delirium induced by histamine h(2) receptor antagonists and proton pump inhibitors in cancer patients. Case Rep Oncol 2012; 5(2): 409-12.
[http://dx.doi.org/10.1159/000341873] [PMID: 22949902]
[163]
Otremba I, Wilczyński K, Szewieczek J. Delirium in the geriatric unit: proton-pump inhibitors and other risk factors. Clin Interv Aging 2016; 11: 397-405.
[PMID: 27103793]
[164]
Ide K, Matsuoka N, Kawakami K. Is the use of proton-pump inhibitors a risk factor for Alzheimer’s disease? molecular mechanisms and clinical implications. Curr Med Chem 2018; 25(18): 2166-74.
[http://dx.doi.org/10.2174/0929867325666180129101049] [PMID: 29376492]
[165]
Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med 2016; 8(6): 595-608.
[http://dx.doi.org/10.15252/emmm.201606210] [PMID: 27025652]
[166]
Hashioka S, Klegeris A, McGeer PL. Proton pump inhibitors reduce interferon-γ-induced neurotoxicity and STAT3 phosphorylation of human astrocytes. Glia 2011; 59(5): 833-40.
[http://dx.doi.org/10.1002/glia.21157] [PMID: 21360757]
[167]
Hashioka S, Klegeris A, McGeer PL. Proton pump inhibitors exert anti-inflammatory effects and decrease human microglial and monocytic THP-1 cell neurotoxicity. Exp Neurol 2009; 217(1): 177-83.
[http://dx.doi.org/10.1016/j.expneurol.2009.02.002] [PMID: 19232345]
[168]
Hashioka S, Klegeris A, Schwab C, McGeer PL. Interferon-gamma-dependent cytotoxic activation of human astrocytes and astrocytoma cells. Neurobiol Aging 2009; 30(12): 1924-35.
[http://dx.doi.org/10.1016/j.neurobiolaging.2008.02.019] [PMID: 18375019]
[169]
Courtney R, Landreth GE. LXR regulation of brain cholesterol: From development to disease. Trends Endocrinol Metab 2016; 27(6): 404-14.
[http://dx.doi.org/10.1016/j.tem.2016.03.018] [PMID: 27113081]
[170]
Yamazaki Y, Zhao N, Caulfield TR, Liu CC, Bu G. Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Nat Rev Neurol 2019; 15(9): 501-18.
[http://dx.doi.org/10.1038/s41582-019-0228-7] [PMID: 31367008]
[171]
Cronican AA, Fitz NF, Pham T, et al. Proton pump inhibitor lansoprazole is a nuclear liver X receptor agonist. Biochem Pharmacol 2010; 79(9): 1310-6.
[http://dx.doi.org/10.1016/j.bcp.2009.12.018] [PMID: 20060385]
[172]
Xu P, Li D, Tang X, et al. LXR agonists: new potential therapeutic drug for neurodegenerative diseases. Mol Neurobiol 2013; 48(3): 715-28.
[http://dx.doi.org/10.1007/s12035-013-8461-3] [PMID: 23625315]
[173]
Skerrett R, Pellegrino MP, Casali BT, Taraboanta L, Landreth GE. Combined liver X receptor/peroxisome proliferator-activated receptor γ agonist treatment reduces amyloid β levels and improves behavior in amyloid precursor protein/presenilin 1 mice. J Biol Chem 2015; 290(35): 21591-602.
[http://dx.doi.org/10.1074/jbc.M115.652008] [PMID: 26163517]
[174]
Sun Y, Fan J, Zhu Z, et al. Small molecule TBTC as a new selective retinoid X receptor α agonist improves behavioral deficit in Alzheimer’s disease model mice. Eur J Pharmacol 2015; 762: 202-13.
[http://dx.doi.org/10.1016/j.ejphar.2015.05.050] [PMID: 26026644]
[175]
Aicardi G. New hope from an old drug: fighting Alzheimer’s disease with the cancer drug bexarotene (targretin)? Rejuvenation Res 2013; 16(6): 524-8.
[http://dx.doi.org/10.1089/rej.2013.1497] [PMID: 24047423]
[176]
Bomben V, Holth J, Reed J, Cramer P, Landreth G, Noebels J. Bexarotene reduces network excitability in models of Alzheimer’s disease and epilepsy. Neurobiol Aging 2014; 35(9): 2091-5.
[http://dx.doi.org/10.1016/j.neurobiolaging.2014.03.029] [PMID: 24767949]
[177]
Muñoz-Cabrera JM, Sandoval-Hernández AG, Niño A, et al. Bexarotene therapy ameliorates behavioral deficits and induces functional and molecular changes in very-old Triple Transgenic Mice model of Alzheimer´s disease. PLoS One 2019; 14(10): e0223578.
[http://dx.doi.org/10.1371/journal.pone.0223578] [PMID: 31596896]
[178]
Pierrot N, Lhommel R, Quenon L, et al. Targretin improves cognitive and biological markers in a patient with Alzheimer’s disease. J Alzheimers Dis 2016; 49(2): 271-6.
[http://dx.doi.org/10.3233/JAD-150405] [PMID: 26444777]
[179]
Cramer PE, Cirrito JR, Wesson DW, et al. ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science 2012; 335(6075): 1503-6.
[http://dx.doi.org/10.1126/science.1217697] [PMID: 22323736]
[180]
Bartzokis G. Inter-species glia differences: Implications for successful translation of transgenic rodent Alzheimer’s disease model treatment using bexarotene. J Prev Alzheimers Dis 2014; 1(1): 46-50.
[PMID: 29261220]
[181]
Mandrekar-Colucci S, Karlo JC, Landreth GE. Mechanisms underlying the rapid peroxisome proliferator-activated receptor-γ-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer’s disease. J Neurosci 2012; 32(30): 10117-28.
[http://dx.doi.org/10.1523/JNEUROSCI.5268-11.2012] [PMID: 22836247]
[182]
Mandrekar-Colucci S, Landreth GE. Nuclear receptors as therapeutic targets for Alzheimer’s disease. Expert Opin Ther Targets 2011; 15(9): 1085-97.
[http://dx.doi.org/10.1517/14728222.2011.594043] [PMID: 21718217]
[183]
Waldum HL, Martinsen TC. Proton pump inhibitors and dementia incidence. JAMA Neurol 2016; 73(8): 1026.
[http://dx.doi.org/10.1001/jamaneurol.2016.1497] [PMID: 27322028]
[184]
Koster KP, Smith C, Valencia-Olvera AC, Thatcher GR, Tai LM, LaDu MJ. Rexinoids as therapeutics for Alzheimer’s disease: role of APOE. Curr Top Med Chem 2017; 17(6): 708-20.
[http://dx.doi.org/10.2174/1568026616666160617090227] [PMID: 27320328]
[185]
Dharmarajan TS. The use and misuse of proton pump inhibitors: an opportunity for deprescribing. J Am Med Dir Assoc 2021; 22(1): 15-22.
[http://dx.doi.org/10.1016/j.jamda.2020.09.046] [PMID: 33321078]

Rights & Permissions Print Cite
Article Metrics
17
1
© 2024 Bentham Science Publishers | Privacy Policy